Mesoblast (MESO) Other Operating Expenses (2014 - 2023)
Mesoblast (MESO) posted Other Operating Expenses of $972000.0 for Q2 2023, down 70.7% sequentially from $3.3 million in Q1 2023, and up 285.5% YoY from $252142.6 in Q2 2022.
Powered by 
Analysis
Mesoblast (MESO) Other Operating Expenses (2014 - 2023) Analysis & Trends
Mesoblast has reported Other Operating Expenses for 10 years, with the latest figure at $972000.0 in Q2 2023.
- Quarterly Other Operating Expenses rose 285.5% year-over-year to $972000.0 in Q2 2023, while the trailing twelve-month figure through Dec 2024 was $972000.0 (down 78.59% YoY) and the FY2025 annual result came in at $3.1 million, up 18.79% from the prior year.
- Other Operating Expenses retreated to $972000.0 in Q2 2023 per MESO's latest filing, from $3.3 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $3.3 million in Q1 2023 and troughed at -$524000.0 in Q2 2022.
- A 5-year average of $270833.3 and a median of $120000.0 in 2020 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2020 and 2022: Other Operating Expenses surged 1603.85% in 2020, then tumbled 471.63% in 2022.
- Over 5 years, Other Operating Expenses stood at $143000.0 in 2019, then soared by 106.99% to $296000.0 in 2020, then tumbled by 176.69% to -$227000.0 in 2021, then surged by 210.57% to $251000.0 in 2022, then jumped by 287.25% to $972000.0 in 2023.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $972000.0, $3.3 million, and $251000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.13 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 972,000.00 |
| Mar 31, 2023 | 3.32 Mn |
| Dec 31, 2022 | 251,000.00 |
| Sep 30, 2022 | -504,000.00 |
| Jun 30, 2022 | -524,000.00 |
| Mar 31, 2022 | 392,000.00 |
| Dec 31, 2021 | -227,000.00 |
| Sep 30, 2021 | -178,000.00 |
| Jun 30, 2021 | 141,000.00 |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 296,000.00 |
| Sep 30, 2020 | 99,000.00 |
| Mar 31, 2020 | -442,000.00 |
| Dec 31, 2019 | 375,000.00 |
| Sep 30, 2019 | -169,000.00 |
| Jun 30, 2019 | -26,000.00 |
| Mar 31, 2019 | -82,000.00 |
| Dec 31, 2018 | -827,000.00 |
| Sep 30, 2018 | -151,000.00 |
| Jun 30, 2018 | 69,000.00 |